Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Recruiting
Phase 1
Phase 2
Interventional Study
Myasthenia Gravis, Generalized
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 85
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 81 (estimated)
- Sponsor
- Aurinia Pharmaceuticals Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key Inclusion Criteria:
* Adult patients (18-85 years old)
* Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG
* Additional inclusion criteria are defined in the protocol
Key Exclusion Criteria:
* Current or medical history of malignancy within the last 5 years
* Pregnant, breastfeed…
Contacts